[Kaposi sarcoma in an HIV-negative hemodialysis patient].
Massanet
C
C
Torguet
P
P
Llistosella
E
E
Casas
M
M
D000328:Adult; D044966:Anti-Retroviral Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004198:Disease Susceptibility; D004317:Doxorubicin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005534:Foot Diseases / Q000188:drug therapy / Q000209:etiology* / Q000532:radiotherapy / Q000821:virology; D005714:Gambia / Q000208:ethnology; D018023:HIV Seronegativity; D019288:Herpesvirus 8, Human / Q000302:isolation & purification*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D008297:Male; D011994:Recombinant Proteins; D016879:Salvage Therapy; D012514:Sarcoma, Kaposi / Q000188:drug therapy / Q000209:etiology* / Q000532:radiotherapy / Q000556:secondary / Q000821:virology; D012878:Skin Neoplasms / Q000188:drug therapy / Q000209:etiology* / Q000532:radiotherapy / Q000821:virology; D013160:Splenic Neoplasms / Q000188:drug therapy / Q000556:secondary
D044966:Anti-Retroviral Agents; D000970:Antineoplastic Agents; D007155:Immunologic Factors; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D004317:Doxorubicin